{
    "id": 25292,
    "fullName": "FGFR1 positive",
    "impact": "unknown",
    "proteinEffect": "unknown",
    "geneVariantDescriptions": [
        {
            "description": "FGFR1 positive indicates the presence of the FGFR1 gene, mRNA, and/or protein.",
            "references": [
                {
                    "id": 275,
                    "pubMedId": null,
                    "title": "External Reference Not Available (N/A)",
                    "url": "https://ckb.jax.org/about/glossaryOfTerms"
                }
            ]
        }
    ],
    "type": "non-specific",
    "gene": {
        "id": 2260,
        "geneSymbol": "FGFR1",
        "terms": [
            "FGFR1",
            "bFGF-R-1",
            "BFGFR",
            "CD331",
            "CEK",
            "ECCL",
            "FGFBR",
            "FGFR-1",
            "FLG",
            "FLT-2",
            "FLT2",
            "HBGFR",
            "HH2",
            "HRTFDS",
            "KAL2",
            "N-SAM",
            "OGD"
        ]
    },
    "variant": "positive",
    "createDate": "08/30/2016",
    "updateDate": "04/18/2018",
    "referenceTranscriptCoordinates": null,
    "partnerGenes": [
        
    ],
    "evidence": [
        {
            "id": 8031,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, synovial sarcoma cells with moderate Fgfr1 expression level demonstrated decreased response to PD173074 in culture (PMID: 27535980).",
            "molecularProfile": {
                "id": 26138,
                "profileName": "FGFR1 positive"
            },
            "therapy": {
                "id": 2948,
                "therapyName": "PD173074",
                "synonyms": null
            },
            "indication": {
                "id": 5485,
                "name": "synovial sarcoma",
                "source": "DOID"
            },
            "responseType": "decreased response",
            "references": [
                {
                    "id": 6537,
                    "pubMedId": 27535980,
                    "title": "Targeting Fibroblast Growth Factor Receptor 1 for Treatment of Soft-Tissue Sarcoma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27535980"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 9351,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, AZD4547 and Rapamune (sirolimus) synergistically inhibited survival of FGFR1-dependent lung large cell carcinoma cells in culture (PMID: 26359452).",
            "molecularProfile": {
                "id": 26138,
                "profileName": "FGFR1 positive"
            },
            "therapy": {
                "id": 4985,
                "therapyName": "AZD4547 + Sirolimus",
                "synonyms": null
            },
            "indication": {
                "id": 4556,
                "name": "lung large cell carcinoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 7121,
                    "pubMedId": 26359452,
                    "title": "Kinome RNAi Screens Reveal Synergistic Targeting of MTOR and FGFR1 Pathways for Treatment of Lung Cancer and HNSCC.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26359452"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 9348,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, AZD4547 and Vistusertib (AZD2014) synergistically inhibited survival of FGFR1-dependent head and neck squamous cell carcinoma cells in culture (PMID: 26359452).",
            "molecularProfile": {
                "id": 26138,
                "profileName": "FGFR1 positive"
            },
            "therapy": {
                "id": 4984,
                "therapyName": "AZD4547 + Vistusertib",
                "synonyms": null
            },
            "indication": {
                "id": 5520,
                "name": "head and neck squamous cell carcinoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 7121,
                    "pubMedId": 26359452,
                    "title": "Kinome RNAi Screens Reveal Synergistic Targeting of MTOR and FGFR1 Pathways for Treatment of Lung Cancer and HNSCC.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26359452"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 12005,
            "approvalStatus": "Phase I",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase I trial, sensitivity to treatment with Rogaratinib (BAY 1163877) was demonstrated in patients with a variety of FGFR-expressing solid tumor types, including long lasting stable disease with resolution of edema in a patient with FGFR1-positive hemangioendothelioma (Ann Oncol 2017, Vol 28, Suppl 5, Abstract #379P; NCT01976741).",
            "molecularProfile": {
                "id": 26138,
                "profileName": "FGFR1 positive"
            },
            "therapy": {
                "id": 2030,
                "therapyName": "Rogaratinib",
                "synonyms": null
            },
            "indication": {
                "id": 255,
                "name": "hemangioma",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 9963,
                    "pubMedId": null,
                    "title": "A novel mRNA-based patient selection strategy identifies fibroblast growth factor receptor (FGFR) inhibitor-sensitive tumors: Results from rogaratinib Phase-1 study",
                    "url": "http://www.esmo.org/Conferences/ESMO-2017-Congress/Abstracts"
                }
            ],
            "ampCapAscoEvidenceLevel": "C",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 8036,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, uterine leiomyosarcoma cells with moderate Fgfr1 expression level demonstrated decreased response to BGJ398 in culture (PMID: 27535980).",
            "molecularProfile": {
                "id": 26138,
                "profileName": "FGFR1 positive"
            },
            "therapy": {
                "id": 674,
                "therapyName": "BGJ398",
                "synonyms": null
            },
            "indication": {
                "id": 5289,
                "name": "uterus leiomyosarcoma",
                "source": "DOID"
            },
            "responseType": "decreased response",
            "references": [
                {
                    "id": 6537,
                    "pubMedId": 27535980,
                    "title": "Targeting Fibroblast Growth Factor Receptor 1 for Treatment of Soft-Tissue Sarcoma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27535980"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 9344,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, AZD4547 and AZD8055 synergistically inhibited survival of FGFR1-dependent lung adenocarcinoma cells in culture (PMID: 26359452).",
            "molecularProfile": {
                "id": 26138,
                "profileName": "FGFR1 positive"
            },
            "therapy": {
                "id": 4983,
                "therapyName": "AZD4547 + AZD8055",
                "synonyms": null
            },
            "indication": {
                "id": 3910,
                "name": "lung adenocarcinoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 7121,
                    "pubMedId": 26359452,
                    "title": "Kinome RNAi Screens Reveal Synergistic Targeting of MTOR and FGFR1 Pathways for Treatment of Lung Cancer and HNSCC.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26359452"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 9345,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, AZD4547 and AZD8055 synergistically inhibited survival of FGFR1-dependent lung large cell carcinoma cells in culture (PMID: 26359452).",
            "molecularProfile": {
                "id": 26138,
                "profileName": "FGFR1 positive"
            },
            "therapy": {
                "id": 4983,
                "therapyName": "AZD4547 + AZD8055",
                "synonyms": null
            },
            "indication": {
                "id": 4556,
                "name": "lung large cell carcinoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 7121,
                    "pubMedId": 26359452,
                    "title": "Kinome RNAi Screens Reveal Synergistic Targeting of MTOR and FGFR1 Pathways for Treatment of Lung Cancer and HNSCC.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26359452"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 9349,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, AZD4547 and Rapamune (sirolimus) synergistically inhibited survival of FGFR1-dependent lung adenocarcinoma cells in culture (PMID: 26359452).",
            "molecularProfile": {
                "id": 26138,
                "profileName": "FGFR1 positive"
            },
            "therapy": {
                "id": 4985,
                "therapyName": "AZD4547 + Sirolimus",
                "synonyms": null
            },
            "indication": {
                "id": 3910,
                "name": "lung adenocarcinoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 7121,
                    "pubMedId": 26359452,
                    "title": "Kinome RNAi Screens Reveal Synergistic Targeting of MTOR and FGFR1 Pathways for Treatment of Lung Cancer and HNSCC.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26359452"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 8030,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, uterine leiomyosarcoma cells with moderate Fgfr1 expression level demonstrated decreased response to PD173074 in culture (PMID: 27535980).",
            "molecularProfile": {
                "id": 26138,
                "profileName": "FGFR1 positive"
            },
            "therapy": {
                "id": 2948,
                "therapyName": "PD173074",
                "synonyms": null
            },
            "indication": {
                "id": 5289,
                "name": "uterus leiomyosarcoma",
                "source": "DOID"
            },
            "responseType": "decreased response",
            "references": [
                {
                    "id": 6537,
                    "pubMedId": 27535980,
                    "title": "Targeting Fibroblast Growth Factor Receptor 1 for Treatment of Soft-Tissue Sarcoma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27535980"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 12000,
            "approvalStatus": "Phase I",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase I trial, sensitivity to treatment with Rogaratinib (BAY 1163877) was demonstrated in patients with a variety of FGFR-expressing solid tumor types, including a partial remission in a patient with FGFR1-positive adenoid cystic carcinoma of the tongue (Ann Oncol 2017, Vol 28, Suppl 5, Abstract #379P; NCT01976741).",
            "molecularProfile": {
                "id": 26138,
                "profileName": "FGFR1 positive"
            },
            "therapy": {
                "id": 2030,
                "therapyName": "Rogaratinib",
                "synonyms": null
            },
            "indication": {
                "id": 4866,
                "name": "salivary gland adenoid cystic carcinoma",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 9963,
                    "pubMedId": null,
                    "title": "A novel mRNA-based patient selection strategy identifies fibroblast growth factor receptor (FGFR) inhibitor-sensitive tumors: Results from rogaratinib Phase-1 study",
                    "url": "http://www.esmo.org/Conferences/ESMO-2017-Congress/Abstracts"
                }
            ],
            "ampCapAscoEvidenceLevel": "C",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 8034,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, synovial sarcoma cells with moderate Fgfr1 expression level demonstrated decreased response to AZD4547 in culture (PMID: 27535980).",
            "molecularProfile": {
                "id": 26138,
                "profileName": "FGFR1 positive"
            },
            "therapy": {
                "id": 654,
                "therapyName": "AZD4547",
                "synonyms": null
            },
            "indication": {
                "id": 5485,
                "name": "synovial sarcoma",
                "source": "DOID"
            },
            "responseType": "decreased response",
            "references": [
                {
                    "id": 6537,
                    "pubMedId": 27535980,
                    "title": "Targeting Fibroblast Growth Factor Receptor 1 for Treatment of Soft-Tissue Sarcoma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27535980"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 8035,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, leiomyosarcoma cells with moderate Fgfr1 expression level demonstrated decreased response to BGJ398 in culture (PMID: 27535980).",
            "molecularProfile": {
                "id": 26138,
                "profileName": "FGFR1 positive"
            },
            "therapy": {
                "id": 674,
                "therapyName": "BGJ398",
                "synonyms": null
            },
            "indication": {
                "id": 1967,
                "name": "leiomyosarcoma",
                "source": "DOID"
            },
            "responseType": "decreased response",
            "references": [
                {
                    "id": 6537,
                    "pubMedId": 27535980,
                    "title": "Targeting Fibroblast Growth Factor Receptor 1 for Treatment of Soft-Tissue Sarcoma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27535980"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 9346,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, AZD4547 and Vistusertib (AZD2014) synergistically inhibited survival of FGFR1-dependent lung large cell carcinoma cells in culture and in cell line xenograft models (PMID: 26359452).",
            "molecularProfile": {
                "id": 26138,
                "profileName": "FGFR1 positive"
            },
            "therapy": {
                "id": 4984,
                "therapyName": "AZD4547 + Vistusertib",
                "synonyms": null
            },
            "indication": {
                "id": 4556,
                "name": "lung large cell carcinoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 7121,
                    "pubMedId": 26359452,
                    "title": "Kinome RNAi Screens Reveal Synergistic Targeting of MTOR and FGFR1 Pathways for Treatment of Lung Cancer and HNSCC.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26359452"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 8032,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, leiomyosarcoma cells with moderate Fgfr1 expression level demonstrated decreased response to AZD4547 in culture (PMID: 27535980).",
            "molecularProfile": {
                "id": 26138,
                "profileName": "FGFR1 positive"
            },
            "therapy": {
                "id": 654,
                "therapyName": "AZD4547",
                "synonyms": null
            },
            "indication": {
                "id": 1967,
                "name": "leiomyosarcoma",
                "source": "DOID"
            },
            "responseType": "decreased response",
            "references": [
                {
                    "id": 6537,
                    "pubMedId": 27535980,
                    "title": "Targeting Fibroblast Growth Factor Receptor 1 for Treatment of Soft-Tissue Sarcoma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27535980"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 8037,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, synovial sarcoma cells with moderate Fgfr1 expression level demonstrated decreased response to BGJ398 in culture (PMID: 27535980).",
            "molecularProfile": {
                "id": 26138,
                "profileName": "FGFR1 positive"
            },
            "therapy": {
                "id": 674,
                "therapyName": "BGJ398",
                "synonyms": null
            },
            "indication": {
                "id": 5485,
                "name": "synovial sarcoma",
                "source": "DOID"
            },
            "responseType": "decreased response",
            "references": [
                {
                    "id": 6537,
                    "pubMedId": 27535980,
                    "title": "Targeting Fibroblast Growth Factor Receptor 1 for Treatment of Soft-Tissue Sarcoma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27535980"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 9347,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, AZD4547 and Vistusertib (AZD2014) synergistically inhibited survival of FGFR1-dependent lung adenocarcinoma cells in culture and in cell line xenograft models (PMID: 26359452).",
            "molecularProfile": {
                "id": 26138,
                "profileName": "FGFR1 positive"
            },
            "therapy": {
                "id": 4984,
                "therapyName": "AZD4547 + Vistusertib",
                "synonyms": null
            },
            "indication": {
                "id": 3910,
                "name": "lung adenocarcinoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 7121,
                    "pubMedId": 26359452,
                    "title": "Kinome RNAi Screens Reveal Synergistic Targeting of MTOR and FGFR1 Pathways for Treatment of Lung Cancer and HNSCC.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26359452"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 8033,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, uterine leiomyosarcoma cells with moderate Fgfr1 expression level demonstrated decreased response to AZD4547 in culture (PMID: 27535980).",
            "molecularProfile": {
                "id": 26138,
                "profileName": "FGFR1 positive"
            },
            "therapy": {
                "id": 654,
                "therapyName": "AZD4547",
                "synonyms": null
            },
            "indication": {
                "id": 5289,
                "name": "uterus leiomyosarcoma",
                "source": "DOID"
            },
            "responseType": "decreased response",
            "references": [
                {
                    "id": 6537,
                    "pubMedId": 27535980,
                    "title": "Targeting Fibroblast Growth Factor Receptor 1 for Treatment of Soft-Tissue Sarcoma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27535980"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 8029,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, leiomyosarcoma cells with moderate Fgfr1 expression level demonstrated decreased response to PD173074 in culture (PMID: 27535980).",
            "molecularProfile": {
                "id": 26138,
                "profileName": "FGFR1 positive"
            },
            "therapy": {
                "id": 2948,
                "therapyName": "PD173074",
                "synonyms": null
            },
            "indication": {
                "id": 1967,
                "name": "leiomyosarcoma",
                "source": "DOID"
            },
            "responseType": "decreased response",
            "references": [
                {
                    "id": 6537,
                    "pubMedId": 27535980,
                    "title": "Targeting Fibroblast Growth Factor Receptor 1 for Treatment of Soft-Tissue Sarcoma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27535980"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 9051,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, hepatocellular carcinoma cell lines treated with AZD4547 demonstrated decreased phosphorylation of FGFR1 and FGFR2, reduced colony formation, and evidence of apoptotic activity in culture (PMID: 26351320).",
            "molecularProfile": {
                "id": 26701,
                "profileName": "FGFR1 pos FGFR2 pos"
            },
            "therapy": {
                "id": 654,
                "therapyName": "AZD4547",
                "synonyms": null
            },
            "indication": {
                "id": 684,
                "name": "hepatocellular carcinoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 6889,
                    "pubMedId": 26351320,
                    "title": "Targeting FGFR Pathway in Human Hepatocellular Carcinoma: Expressing pFGFR and pMET for Antitumor Activity.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26351320"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 9053,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, PHA-665752 treatment did not result in decreased colony formation or reduced phosphorylation levels of FGFR1 and FGFR2 in hepatocellular carcinoma cells in culture (PMID: 26351320).",
            "molecularProfile": {
                "id": 26701,
                "profileName": "FGFR1 pos FGFR2 pos"
            },
            "therapy": {
                "id": 2162,
                "therapyName": "PHA-665752",
                "synonyms": null
            },
            "indication": {
                "id": 684,
                "name": "hepatocellular carcinoma",
                "source": "DOID"
            },
            "responseType": "no benefit",
            "references": [
                {
                    "id": 6889,
                    "pubMedId": 26351320,
                    "title": "Targeting FGFR Pathway in Human Hepatocellular Carcinoma: Expressing pFGFR and pMET for Antitumor Activity.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26351320"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 9499,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, acute myeloid leukemia cells harboring a FLT3 internal tandem duplication and expressing FGFR1 demonstrated sensitivity to treatment with PD173074 in the presence of FGF2 ligand in culture, resulting in decreased cell viability (PMID: 27671675).",
            "molecularProfile": {
                "id": 26859,
                "profileName": "FGF2 pos FGFR1 pos FLT3 exon 14 ins"
            },
            "therapy": {
                "id": 2948,
                "therapyName": "PD173074",
                "synonyms": null
            },
            "indication": {
                "id": 9119,
                "name": "acute myeloid leukemia",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 7227,
                    "pubMedId": 27671675,
                    "title": "FGF2 from Marrow Microenvironment Promotes Resistance to FLT3 Inhibitors in Acute Myeloid Leukemia.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27671675"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 9502,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, the combination of Quizartinib (AC220) and PD173074 resulted in a synergistic effect in the presence of FGF2 ligand in acute myeloid leukemia cells harboring a FLT3 internal tandem duplication and expressing FGFR1 in culture (PMID: 27671675).",
            "molecularProfile": {
                "id": 26859,
                "profileName": "FGF2 pos FGFR1 pos FLT3 exon 14 ins"
            },
            "therapy": {
                "id": 5041,
                "therapyName": "PD173074 + Quizartinib",
                "synonyms": null
            },
            "indication": {
                "id": 9119,
                "name": "acute myeloid leukemia",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 7227,
                    "pubMedId": 27671675,
                    "title": "FGF2 from Marrow Microenvironment Promotes Resistance to FLT3 Inhibitors in Acute Myeloid Leukemia.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27671675"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 9500,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, acute myeloid leukemia cells harboring a FLT3 internal tandem duplication and expressing FGFR1 demonstrated resistance to treatment with Quizartinib (AC220) in the presence of FGF2 ligand in culture (PMID: 27671675).",
            "molecularProfile": {
                "id": 26859,
                "profileName": "FGF2 pos FGFR1 pos FLT3 exon 14 ins"
            },
            "therapy": {
                "id": 882,
                "therapyName": "Quizartinib",
                "synonyms": null
            },
            "indication": {
                "id": 9119,
                "name": "acute myeloid leukemia",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 7227,
                    "pubMedId": 27671675,
                    "title": "FGF2 from Marrow Microenvironment Promotes Resistance to FLT3 Inhibitors in Acute Myeloid Leukemia.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27671675"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        }
    ],
    "molecularProfiles": [
        {
            "id": 26138,
            "profileName": "FGFR1 positive",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 26701,
            "profileName": "FGFR1 pos FGFR2 pos",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 26859,
            "profileName": "FGF2 pos FGFR1 pos FLT3 exon 14 ins",
            "profileTreatmentApproaches": [
                
            ]
        }
    ],
    "allTranscriptCoordinates": [
        
    ]
}